JP2021521159A5 - - Google Patents
Info
- Publication number
- JP2021521159A5 JP2021521159A5 JP2020555387A JP2020555387A JP2021521159A5 JP 2021521159 A5 JP2021521159 A5 JP 2021521159A5 JP 2020555387 A JP2020555387 A JP 2020555387A JP 2020555387 A JP2020555387 A JP 2020555387A JP 2021521159 A5 JP2021521159 A5 JP 2021521159A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- sugar
- preparation according
- item
- surfactant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023189255A JP7793581B2 (ja) | 2018-04-10 | 2023-11-06 | 抗体製剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201841013646 | 2018-04-10 | ||
| IN201841013646 | 2018-04-10 | ||
| PCT/IN2019/050292 WO2019198100A1 (en) | 2018-04-10 | 2019-04-10 | Antibody formulation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023189255A Division JP7793581B2 (ja) | 2018-04-10 | 2023-11-06 | 抗体製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021521159A JP2021521159A (ja) | 2021-08-26 |
| JP2021521159A5 true JP2021521159A5 (enExample) | 2022-04-15 |
Family
ID=68163986
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020555387A Pending JP2021521159A (ja) | 2018-04-10 | 2019-04-10 | 抗体製剤 |
| JP2023189255A Active JP7793581B2 (ja) | 2018-04-10 | 2023-11-06 | 抗体製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023189255A Active JP7793581B2 (ja) | 2018-04-10 | 2023-11-06 | 抗体製剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12030948B2 (enExample) |
| EP (1) | EP3773694A4 (enExample) |
| JP (2) | JP2021521159A (enExample) |
| CN (1) | CN112218654A (enExample) |
| AU (1) | AU2019253070A1 (enExample) |
| BR (1) | BR112020020707A2 (enExample) |
| CO (1) | CO2020013552A2 (enExample) |
| SG (1) | SG11202009874QA (enExample) |
| WO (1) | WO2019198100A1 (enExample) |
| ZA (1) | ZA202006263B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10994011B2 (en) | 2015-12-18 | 2021-05-04 | Astellas Pharma Inc. | Pharmaceutical composition comprising anti-human TSLP receptor antibody |
| US12024561B2 (en) * | 2018-04-10 | 2024-07-02 | Dr. Reddy's Laboratories Limited | Stable antibody formulation |
| WO2021228760A1 (en) * | 2020-05-11 | 2021-11-18 | Medimmune Limited | Formulations of anti-il-33 antibodies |
| WO2024098180A1 (en) * | 2022-11-07 | 2024-05-16 | Wuxi Biologics (Hong Kong) Limited | Pharmaceutical compositions comprising anti-human tslp receptor antibodies and methods of using the same |
| US20230340131A1 (en) * | 2020-11-12 | 2023-10-26 | Dr. Reddy’S Laboratories Limited | Stable aqueous high concentration formulation of integrin antibody |
| US20240100158A1 (en) * | 2021-01-20 | 2024-03-28 | Dr. Reddy’S Laboratories Limited | Freeze dried antibody formulations and methods thereof |
| JP2024516293A (ja) * | 2021-05-07 | 2024-04-12 | ドクター レディズ ラボラトリーズ リミテッド | 抗体製剤の安定性を向上させる方法 |
| WO2022253994A1 (en) * | 2021-06-04 | 2022-12-08 | Polpharma Biologics S.A. | Vedolizumab formulation |
| CN113813377A (zh) * | 2021-09-07 | 2021-12-21 | 杭州远大生物制药有限公司 | 抗α4β7抗体制剂及其应用 |
| EP4615502A1 (en) | 2022-11-07 | 2025-09-17 | Upstream Bio, Inc. | Pharmaceutical compositions comprising anti-human tslp receptor antibodies and methods of using the same |
| EP4720125A1 (en) | 2023-05-30 | 2026-04-08 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
| EP4762093A1 (en) | 2023-08-14 | 2026-06-24 | Paragon Therapeutics, Inc. | Alpha 4 beta 7 integrin binding proteins and methods of use |
| WO2025041000A1 (en) * | 2023-08-21 | 2025-02-27 | Intas Pharmaceuticals Ltd. | STABLE LIQUID CITRATE FREE FORMULATION OF AN ANTI-α4β7 ANTIBODY |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103040732B (zh) * | 2003-02-10 | 2015-04-01 | 伊兰药品公司 | 免疫球蛋白制剂及其制备方法 |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| US20090208492A1 (en) * | 2007-06-14 | 2009-08-20 | Elan Pharmaceuticals, Inc. | Lyophilized Immunoglobulin Formulations and Methods of Preparation |
| WO2012076670A2 (en) | 2010-12-10 | 2012-06-14 | Novartis Ag | Antibody formulation |
| UY34054A (es) * | 2011-05-02 | 2012-11-30 | Millennium Pharm Inc | FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7 |
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| US20210322549A1 (en) * | 2015-07-17 | 2021-10-21 | Coherus Biosciences, Inc. | Stable Aqueous Formulations of Natalizumab |
| WO2019147824A1 (en) * | 2018-01-26 | 2019-08-01 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor |
| EP3884276A2 (en) * | 2018-11-23 | 2021-09-29 | Katholieke Universiteit Leuven | Predicting a treatment response in inflammatory bowel disease |
-
2019
- 2019-04-10 SG SG11202009874QA patent/SG11202009874QA/en unknown
- 2019-04-10 BR BR112020020707-1A patent/BR112020020707A2/pt unknown
- 2019-04-10 WO PCT/IN2019/050292 patent/WO2019198100A1/en not_active Ceased
- 2019-04-10 EP EP19784340.2A patent/EP3773694A4/en active Pending
- 2019-04-10 JP JP2020555387A patent/JP2021521159A/ja active Pending
- 2019-04-10 CN CN201980037792.0A patent/CN112218654A/zh active Pending
- 2019-04-10 AU AU2019253070A patent/AU2019253070A1/en not_active Abandoned
- 2019-04-10 US US17/045,380 patent/US12030948B2/en active Active
-
2020
- 2020-10-08 ZA ZA2020/06263A patent/ZA202006263B/en unknown
- 2020-10-28 CO CONC2020/0013552A patent/CO2020013552A2/es unknown
-
2023
- 2023-11-06 JP JP2023189255A patent/JP7793581B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7793581B2 (ja) | 抗体製剤 | |
| CN102712677B (zh) | 脂肽组合物和相关方法 | |
| US12251474B2 (en) | Process for lyophilized pharmaceutical formulations of a therapeutic protein | |
| JP2021521171A5 (enExample) | ||
| JP2015091902A5 (enExample) | ||
| JP2013511522A (ja) | ダプトマイシン製剤 | |
| US20170189528A1 (en) | Stable aqueous adalimumab formulation | |
| JP2010511665A5 (enExample) | ||
| JP2024508762A5 (enExample) | ||
| CN102202688A (zh) | 稳定、干燥的轮状病毒疫苗、其组合物和制备其的方法 | |
| TW202535466A (zh) | 抗-il-23p19抗體調配物 | |
| RU2018129077A (ru) | Стабильная фармацевтическая композиция | |
| JP2023516957A5 (enExample) | ||
| US12491229B2 (en) | Stabilized peptide composition | |
| KR20220034053A (ko) | 재조합 단백질의 안정적인 제형 | |
| JP2021521168A5 (enExample) | ||
| RU2020136713A (ru) | Композиция из антител | |
| US9907835B2 (en) | Stable Factor VIII formulations with low sugar-glycine | |
| KR102692727B1 (ko) | 수성 제제 및 주사기 내 수성 제제, 및 항체 단백질 탈응집제 및 항체 단백질 탈응집 방법 | |
| WO2022200811A1 (en) | Modified chimeric coronavirus spike protein for enhancement of viral titers | |
| TW201607564A (zh) | 經安定化的多肽水性製劑 | |
| HK40033832B (en) | Process for lyophilized pharmaceutical formulation of a therapeutic protein | |
| RU2019136641A (ru) | Устойчивая жидкая фармацевтическая композиция | |
| TH132129A (th) | ตัวเติมเนื้อยาเพื่อคงความเสถียรสำหรับวัคซีนไวรัสครบส่วนที่หมดฤทธิ์ |